Loading…
Loading…
Vanguard Health Care ETF provides significantly broader exposure with 411 holdings compared to 100 for iShares U.S. Healthcare ETF. The Vanguard fund maintains a lower expense ratio of 0.09%, while the iShares fund charges 0.37%.
Shares of iShares U.S. Healthcare ETF (NYSEARCA:IYH - Get Free Report) saw unusually-high trading volume on Friday. Approximately 614,797 shares changed hands during mid-day trading, a decline of 22% from the previous session's volume of 789,866 shares. The stock last traded at $74.7480 and had previously closed at $74.49. iShares U.S. Healthcare ETF Stock Down
First Citizens Bank and Trust Co. purchased a new stake in iShares U.S. Healthcare ETF (NYSEARCA:IYH) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 9,175 shares of the company's stock, valued at approximately $657,000. A number of other institutional
The iShares U.S. Healthcare ETF offers a lower expense ratio and a higher dividend yield than the iShares Biotechnology ETF. The iShares Biotechnology ETF provides concentrated exposure to over 200 biotech companies, while the iShares U.S. Healthcare ETF holds 100 diverse healthcare positions.
iShares Global Healthcare ETF provides broad exposure to international medical companies with a higher dividend yield than its domestic counterpart. iShares U.S. Healthcare ETF concentrates on American companies and has produced higher total returns over the past year and five-year periods.
The Invesco Nasdaq Biotechnology ETF carries a lower expense ratio and delivered higher total returns over the trailing 12 months than the iShares U.S. Healthcare ETF. The iShares U.S. Healthcare ETF provides broader industry diversification across the medical sector, while the Invesco Nasdaq Biotechnology ETF focuses strictly on biotechnology and pharmaceuticals.
iShares U.S. Healthcare ETF offers a more diversified portfolio and lower expense ratio than Invesco Biotechnology & Genome ETF. Invesco Biotechnology & Genome ETF delivered a higher 1-year total return but has experienced significantly larger historical drawdowns.
IHE's concentrated pharma focus delivered 50% gains versus IYH's 27.4%, though the broader healthcare fund offers more diversification and $3.9B in assets.